Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users
- PMID: 27211522
- DOI: 10.3109/00952990.2016.1167215
Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users
Abstract
Background: ALO-02, comprising pellets of extended-release oxycodone surrounding sequestered naltrexone, is intended to deter abuse.
Objective: Determine the abuse potential of intravenous oxycodone combined with naltrexone, which represents simulated crushed ALO-02 in solution, compared with intravenous oxycodone in nondependent, recreational opioid users.
Methods: A randomized, double-blind, placebo-controlled, three-way crossover study with naloxone challenge, drug discrimination, and treatment phases. Intravenous treatments included oxycodone hydrochloride 20 mg, oxycodone hydrochloride 20 mg plus naltrexone hydrochloride 2.4 mg (simulated crushed ALO-02 20 mg/2.4 mg), or placebo (0.9% sodium chloride for injection). Primary end points were peak effects (Emax) and area under the effects curve within 2 h postdose (AUE0-2h) on drug liking and high visual analog scales.
Results: Thirty-three participants were randomized into treatment phase, and 29 completed all treatments. Study validity was confirmed with statistically significant differences in Emax for drug liking and high (p < 0.0001) between intravenous oxycodone and placebo. Intravenous simulated crushed ALO-02 resulted in significantly lower scores than oxycodone on drug liking (Emax: 58.2 vs. 92.4; AUE0-2h: 104.3 vs. 152.4) and high (Emax: 17.2 vs. 93.1; AUE0-2h: 12.0 vs. 133.6), respectively (p < 0.0001, all comparisons). More participants experienced adverse events after intravenous oxycodone (n = 27 [90%]) versus intravenous simulated crushed ALO-02 (n = 4 [12.5%]) or placebo (n = 2 [6.5%]).
Conclusion: Intravenous administration of simulated crushed ALO-02 resulted in significantly lower abuse potential, as assessed by subjective ratings of drug liking and high, than intravenous oxycodone in nondependent, recreational opioid users. This suggests that injection of ALO-02 may not be as desirable to recreational opioid users compared with oxycodone taken for nonmedical reasons.
Keywords: Abuse potential; drug liking; intravenous; naltrexone; opioids; oxycodone.
Similar articles
-
Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.J Clin Pharmacol. 2015 Dec;55(12):1351-61. doi: 10.1002/jcph.552. Epub 2015 Jul 2. J Clin Pharmacol. 2015. PMID: 26011742 Clinical Trial.
-
Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.Pain Med. 2017 Jun 1;18(6):1077-1088. doi: 10.1093/pm/pnw178. Pain Med. 2017. PMID: 27550954 Free PMC article. Clinical Trial.
-
Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.J Opioid Manag. 2017 Nov/Dec;13(6):449-464. doi: 10.5055/jom.2017.0421. J Opioid Manag. 2017. PMID: 29308591 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):823-31. doi: 10.1080/17425255.2016.1191469. Epub 2016 Jun 7. Expert Opin Drug Metab Toxicol. 2016. PMID: 27253690 Review.
-
Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.Pain Physician. 2011 Jul-Aug;14(4):391-406. Pain Physician. 2011. PMID: 21785483 Review.
Cited by
-
Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study.Ther Adv Drug Saf. 2019 Feb 1;10:2042098618821274. doi: 10.1177/2042098618821274. eCollection 2019. Ther Adv Drug Saf. 2019. PMID: 30746121 Free PMC article.
-
Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.Hum Vaccin Immunother. 2019;15(4):909-917. doi: 10.1080/21645515.2018.1558697. Epub 2019 Feb 20. Hum Vaccin Immunother. 2019. PMID: 30625019 Free PMC article.
-
Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats.J Pharmacol Exp Ther. 2018 May;365(2):346-353. doi: 10.1124/jpet.117.247049. Epub 2018 Mar 13. J Pharmacol Exp Ther. 2018. PMID: 29535156 Free PMC article.
-
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments.Pharmacol Rev. 2023 Nov;75(6):1062-1118. doi: 10.1124/pharmrev.121.000506. Epub 2023 Jun 15. Pharmacol Rev. 2023. PMID: 37321860 Free PMC article. Review.
-
Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product.J Pain Res. 2018 Feb 8;11:301-311. doi: 10.2147/JPR.S127602. eCollection 2018. J Pain Res. 2018. PMID: 29445297 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources